Long-Term Outcomes in Patients with EGFR Positive Lung Adenocarcinoma and Subgroup Analysis Based on Presence of Liver Metastases

• Published in: Current issues in molecular biology 2024-11, Vol.46 (12), p.13431-13442
• Main Authors: Ćeriman Krstić, Vesna, Soldatović, Ivan, Samardžić, Natalija, Gajić, Milija, Kontić, Milica, Reljić, Aleksandar, Savić, Milan, Roksandić Milenković, Marina, Jovanović, Dragana
• Format: Article
• Language: English
• Subjects: combination therapies; EGFR; immunotherapy; liver metastases; NSCLC; radiotherapy
• ISSN: 1467-3045; 1467-3037; 1467-3045
• DOI: 10.3390/cimb46120801

Lung cancer represents the most common cause of cancer related death. Patients with non-small cell lung cancer (NSCLC) and liver metastases (LM) have worse prognosis with an overall survival (OS) of three to six months. The aim of this study was to investigate long-term outcomes in patients with EGFR mutated (EGFRmut) lung adenocarcinoma as well as the presence of LM. (A total of 105 patients were included in the analysis). They were divided into two groups based on the presence of LM. OS was 13 months for the whole group and also 13 months for patients with and without LM. The 9-year survival rate for patients with and without LM was 12.5% and 3.4%, respectively. Further, the 9-year survival rate for the whole group of patients was 4.8%. There are few data about survival rates beyond 5 years for patients with locally advanced and metastatic EGFRmut NSCLC, mainly because patients with lung cancer rarely live for such a long time. Regarding patients with liver metastases, the results of our study showed similar outcomes compared to patients without LM. As these patients represent a significant number of patients, we need a wider range of therapeutic options. It might be that combination therapies represent a better therapeutic option.